LGL Group (NYSEAMERICAN:LGL) Posts Quarterly Earnings Results, Misses Estimates By $0.09 EPS

LGL Group (NYSEAMERICAN:LGL) issued its earnings results on Monday. The industrial products company reported ($0.02) earnings per share for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.09), reports. LGL Group had a net margin of 16.50% and a return on equity of 1.66%. The firm had revenue of $0.80 million during the quarter, compared to analyst estimates of $9.10 million.

LGL Group Stock Up 2.2%

Shares of NYSEAMERICAN LGL traded up $0.15 during midday trading on Wednesday, hitting $7.10. The stock had a trading volume of 4,454 shares, compared to its average volume of 12,501. LGL Group has a 1-year low of $5.45 and a 1-year high of $9.74. The company has a market capitalization of $46.36 million, a price-to-earnings ratio of 64.55 and a beta of 0.31. The company has a fifty day moving average price of $7.14 and a 200 day moving average price of $6.48.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in LGL Group stock. Citadel Advisors LLC bought a new stake in LGL Group, Inc. (The) (NYSEAMERICAN:LGL) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 13,515 shares of the industrial products company’s stock, valued at approximately $90,000. Citadel Advisors LLC owned approximately 0.25% of LGL Group as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 30.28% of the company’s stock.

About LGL Group

LGL Group Inc is a United States–based company specializing in the development and commercialization of digital pathology and molecular imaging systems for research and clinical laboratories. The company’s core focus lies in enabling high-resolution visualization and quantitative analysis of tissue samples, helping scientists and pathologists accelerate biomarker discovery and diagnostic workflows. LGL Group’s platform combines advanced optics, automated slide scanning and image analysis software to deliver end-to-end solutions tailored to oncology, immunology and neuroscience research.

The company’s flagship offerings include whole-slide scanners capable of rapid, high-throughput scanning at resolutions suited for detailed morphometric and fluorescence studies.